Tissue Regenix (TRX) AI Stock Analysis

• Market Cap: £5.16M
• Dividend Yield: N/A
• Average Volume (3M): 778.41K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.41
• Revenue Growth: -20.31%
• EPS Growth: -19.35%
• Country: UK
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 71,395,640
• 10 Day Avg. Volume: 807,890
• 30 Day Avg. Volume: 778,414
• PEG Ratio: 1.27
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 1.85
• P/FCF Ratio: -9.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: 7.00p ▼(-3.45% Downside)

Tissue Regenix faces significant financial and operational challenges, reflected in its negative earnings and reliance on external funding. Technical indicators suggest bearish momentum, and recent corporate events highlight financial instability. While there are strategic efforts to improve, the immediate outlook remains cautious.

Positive Factors

Intellectual Property Strength

Securing an EU patent and MDR certification enhances Tissue Regenix's competitive edge by protecting its technology and ensuring compliance with stringent medical regulations, which can facilitate market expansion and product adoption.

Product Line Expansion

The increase in orders for demineralized bone matrix products indicates growing demand and acceptance in the market, which can drive revenue growth and strengthen the company's position in the regenerative medicine sector.

Growth in dCELL Business

The 10% growth in the dCELL business demonstrates successful market penetration and product effectiveness, suggesting a robust segment that can contribute to long-term revenue stability and expansion opportunities.

Negative Factors

Revenue Decline

The decline in group revenues indicates challenges in maintaining sales momentum, which could affect the company's ability to achieve profitability and sustain operations without strategic adjustments.

Regulatory Challenges

Regulatory delays can hinder product distribution and revenue generation, posing risks to the company's market access and operational efficiency, which are critical for long-term growth and stability.

Financial Strain

Financial strain from reduced revenues and profitability increases reliance on external funding, which can limit financial flexibility and pose risks to the company's ability to invest in growth initiatives.

Tissue Regenix Business Overview & Revenue Model

Company Description

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

How the Company Makes Money

Tissue Regenix generates revenue primarily through the sale of its tissue-based products to hospitals, clinics, and other healthcare providers. The company's revenue model is built on the commercialization of its advanced wound care and orthopedic products, which are sold under various brand names. TRX also benefits from partnerships with healthcare institutions and distributors that help expand its market reach. Additionally, the company may engage in collaborations or licensing agreements that provide upfront payments and royalties, further contributing to its earnings. The growth of its revenue is influenced by the increasing demand for regenerative medicine solutions and advancements in surgical techniques.

Tissue Regenix Financial Statement Overview

Summary

Tissue Regenix shows signs of operational improvement with better gross margins and reduced operating losses. However, the path to profitability remains challenging with continued net losses and negative cash flows. While the equity position provides some financial stability, increased leverage and reliance on external funding could pose risks.

Income Statement

The company has shown improvement in its gross profit margin, increasing from previous years, indicating better cost management. However, the net profit margin remains negative, reflecting ongoing challenges in achieving profitability. Revenue growth has been inconsistent, with fluctuations observed over the years. While the EBIT and EBITDA margins have improved, they remain low, highlighting the need for further operational efficiencies.

Balance Sheet

The company maintains a strong equity base, with a healthy equity ratio, suggesting financial stability. However, the debt-to-equity ratio has increased, indicating higher leverage, which could pose risks if not managed carefully. Return on equity remains negative due to net losses, underscoring the need for improved profitability to enhance shareholder value.

Cash Flow

Cash flow from operations has been negative, impacting the company's ability to internally fund its activities. The free cash flow remains negative, highlighting potential liquidity constraints. The company has relied on financing activities to support its cash position, which could be unsustainable in the long term if operating cash flows do not improve.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.80M	28.65M	29.49M	24.48M	19.75M	12.83M
Gross Profit	5.77M	13.62M	14.04M	9.14M	5.63M	5.13M
EBITDA	5.00K	1.36M	446.00K	-1.04M	-3.04M	-9.03M
Net Income	-934.00K	-713.00K	-1.71M	-2.69M	-4.79M	-9.71M
Balance Sheet
Total Assets	47.19M	45.35M	43.24M	38.27M	34.13M	36.73M
Cash, Cash Equivalents and Short-Term Investments	1.07M	1.87M	4.65M	4.95M	5.69M	9.55M
Total Debt	11.00M	10.46M	9.39M	9.61M	7.95M	7.22M
Total Liabilities	18.56M	16.29M	13.89M	13.00M	9.47M	8.88M
Stockholders Equity	29.36M	29.82M	30.15M	31.25M	25.35M	28.46M
Cash Flow
Free Cash Flow	-252.00K	-5.70M	177.00K	-2.29M	-3.93M	-6.84M
Operating Cash Flow	-202.00K	-1.64M	1.04M	-1.41M	-2.45M	-5.47M
Investing Cash Flow	-592.00K	-4.06M	-837.00K	-1.08M	-2.04M	-1.86M
Financing Cash Flow	-2.00K	3.28M	-1.51M	910.00K	-192.00K	17.68M

Tissue Regenix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TRX, the sentiment is Negative. The current price of 7.25 is above the 20-day moving average (MA) of 7.25, below the 50-day MA of 7.55, and below the 200-day MA of 25.74, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 12.03 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TRX.

Tissue Regenix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AREC	56 Neutral	£27.94M	-3.35	-204.29%	―	3.31%	21.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRX	49 Neutral	£5.16M	-4.90	-5.41%	―	-20.31%	-19.35%
SAR	47 Neutral	£20.71M	-6.25	-202.14%	―	―	23.76%
OBD	40 Underperform	£6.26M	-0.11	-333.59%	―	45.22%	55.71%

Tissue Regenix Corporate Events

Tissue Regenix Secures £17.5M Funding and Plans AIM Delisting

Tissue Regenix has announced a conditional fundraising of £17.5 million through Secured Convertible Loan Notes to Harwood Private Equity, an existing substantial shareholder. Alongside this, the company plans to cancel its AIM listing due to disproportionate costs and limited benefits, re-register as a private entity, and adopt new articles of association. This strategic move is intended to streamline operations and provide a more cost-effective capital access, impacting its market presence and shareholder engagement.

Tissue Regenix Secures Emergency Funding Amidst Strategic Financial Planning

Tissue Regenix has secured an emergency overdraft of $500K to maintain operations and is in discussions with shareholders regarding further funding needs. The company plans to raise funds through a convertible loan note, pending shareholder approval, to support revenue growth and operational stability.

Tissue Regenix Faces Urgent Capital Raise Amid Financial Challenges

Tissue Regenix has announced an urgent need to raise capital due to a substantial backlog of creditors and limited cash reserves, following a restatement of revenue numbers for the financial year 2024. The company is in discussions with major shareholders to raise approximately £5 million through a convertible loan note, which is crucial for its continued operation and subject to shareholder approval.

Tissue Regenix Suspends Trading to Address Financial Review

Tissue Regenix has temporarily suspended trading of its shares on AIM to allow its new leadership team to review and address financial discrepancies related to the restatement of revenue numbers for the fiscal year 2024. The company is implementing strict financial controls and aims to reduce costs by over $2 million, with a commitment to business recovery and sustainable growth.

Tissue Regenix Strengthens Leadership with New Board Appointment

Tissue Regenix has announced that Kirsten Lund, the Chief Financial Officer, has joined the company’s board with immediate effect. This move is part of the company’s strategic efforts to strengthen its leadership team, potentially enhancing its operational efficiency and market positioning in the regenerative medical devices industry.

Tissue Regenix Announces Financial Restatement and Leadership Changes

Tissue Regenix announced significant financial and organizational changes, including a restatement of FY24 adjusted EBITDA from a profit to a loss and the departure of CEO Daniel Lee. The company has appointed Jay LeCoque as Acting CEO and Executive Chairman and reappointed Kirsten Lund as CFO to implement strict financial controls and a cost reduction initiative. These changes aim to improve financial performance and expand the company’s market presence, with a focus on sustainable, long-term growth.

Tissue Regenix Reports Revenue Decline Amid Regulatory Challenges

Tissue Regenix Group PLC reported a 6% decrease in revenue for the first half of 2025, primarily due to commercial, regulatory, and reimbursement challenges. Despite a downturn in trading and a reduced cash position, the company remains optimistic about its long-term growth prospects, supported by recent certifications and patents, as well as an expanded distribution network. Management changes and strategic focus on sustainable revenue opportunities aim to enhance shareholder value.

Tissue Regenix Faces Revenue Decline Amid Regulatory Challenges

Tissue Regenix Group reported a 6% revenue decline for the first half of 2025, attributed to commercial, regulatory, and reimbursement challenges. The company’s BioRinse® and dCELL® product lines faced revenue decreases, while the gross profit margin fell to 42% due to lower production yields. Despite these setbacks, the company received CE certification for OrthoPure® XT and a European patent for dCELL® technology, and expanded its dCELL distribution network. Management changes were also announced, with new appointments and resignations. The company remains optimistic about future growth and aims to improve trading and cash flow in the long term.

Tissue Regenix to Release Interim Results with Investor Presentation

Tissue Regenix announced that it will release its interim results on 30 September 2025, with a live online presentation hosted by the CEO and Executive Chairman. This event is open to current and potential shareholders, indicating the company’s commitment to transparency and engagement with its stakeholders.

Tissue Regenix Appoints Jay LeCoque as Executive Chairman Amid Board Reshuffle

Tissue Regenix has announced significant changes to its Board of Directors, with Jay LeCoque appointed as the new Executive Chairman. LeCoque brings over 25 years of experience in senior management within the life sciences sector, which is expected to strengthen the company’s growth and earnings. The resignations of Jonathan Glenn and Trevor Phillips from the Board were also announced, with the company expressing gratitude for their contributions. The appointment of LeCoque is seen as a strategic move to enhance the company’s position in the global healthcare and clinical life sciences market.